---
document_datetime: 2026-02-03 15:05:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sapropterin-dipharma.html
document_name: sapropterin-dipharma.html
version: success
processing_time: 0.1201745
conversion_datetime: 2026-02-04 15:08:19.908365
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.12)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sapropterin Dipharma

[RSS](/en/individual-human-medicine.xml/67526)

##### Authorised

This medicine is authorised for use in the European Union

sapropterin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sapropterin Dipharma](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sapropterin Dipharma is a medicine that is used to treat high blood levels of phenylalanine in adults and children of all ages with the genetic disorders phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.

Patients with these disorders cannot process the amino acid phenylalanine from dietary protein. As a result, phenylalanine builds up in the blood to abnormally high levels, causing problems in the nervous system.

Sapropterin Dipharma contains the active substance sapropterin and is a 'generic medicine'. This means that Sapropterin Dipharma contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Kuvan. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Sapropterin Dipharma used?

Sapropterin Dipharma is available as soluble tablets or as a powder, to be dissolved in water and drunk. The medicine can only be obtained with a prescription and treatment must be started and supervised by a doctor who has experience in treating PKU and BH4 deficiency. It is important that patients continue with a diet low in phenylalanine and protein when taking Sapropterin Dipharma, and intake of phenylalanine and protein must be monitored and adjusted to make sure that blood phenylalanine levels and nutritional balance are controlled. Sapropterin Dipharma is intended for long-term use.

The starting dose of Sapropterin Dipharma depends on the patient's weight. The dose is then adjusted depending on blood levels of amino acids, including phenylalanine. Sapropterin Dipharma is taken with a meal at the same time every day, preferably in the morning. For some patients with BH4 deficiency, the dose may need to be divided into 2 or 3 doses over the course of the day to get the best effect.

A satisfactory response is defined as a reduction in blood phenylalanine levels of at least 30% or to a level determined by the doctor. If this has been achieved after one month, the patient is classified as a 'responder' and can continue taking Sapropterin Dipharma.

For more information about using Sapropterin Dipharma, see the package leaflet or contact your doctor or pharmacist.

## How does Sapropterin Dipharma work?

The high levels of phenylalanine in the blood are due to a problem with the breakdown of phenylalanine through the enzyme 'phenylalanine hydroxylase'. Patients with PKU have defective versions of the enzyme, and patients with BH4 deficiency have low levels of BH4, a 'cofactor' that this enzyme needs to work properly.

The active substance in Sapropterin Dipharma, sapropterin, is a synthetic copy of BH4. In patients with PKU, it works by enhancing the activity of the defective enzyme, while in patients with BH4 deficiency it replaces the missing cofactor. These actions help restore the ability of the enzyme to convert phenylalanine into tyrosine, thereby reducing phenylalanine levels in the blood.

## How has Sapropterin Dipharma been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Kuvan, and do not need to be repeated for Sapropterin Dipharma.

As for every medicine, the company provided data on the quality of Sapropterin Dipharma. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Sapropterin Dipharma?

Because Sapropterin Dipharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Sapropterin Dipharma authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Sapropterin Dipharma has been shown to have comparable quality and to be bioequivalent to Kuvan. Therefore, the Agency's view was that, as for Kuvan, the benefits of Sapropterin Dipharma outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sapropterin Dipharma?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sapropterin Dipharma have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sapropterin Dipharma are continuously monitored. Suspected side effects reported with Sapropterin Dipharma are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sapropterin Dipharma

Sapropterin Dipharma received a marketing authorisation valid throughout the EU on 16 February 2022.

Sapropterin Dipharma : EPAR - Medicine Overview

Reference Number: EMA/4952/2022

English (EN) (146.65 KB - PDF)

**First published:** 16/03/2022

[View](/en/documents/overview/sapropterin-dipharma-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-313)

български (BG) (157.95 KB - PDF)

**First published:**

16/03/2022

[View](/bg/documents/overview/sapropterin-dipharma-epar-medicine-overview_bg.pdf)

español (ES) (135.46 KB - PDF)

**First published:**

16/03/2022

[View](/es/documents/overview/sapropterin-dipharma-epar-medicine-overview_es.pdf)

čeština (CS) (155.45 KB - PDF)

**First published:**

16/03/2022

[View](/cs/documents/overview/sapropterin-dipharma-epar-medicine-overview_cs.pdf)

dansk (DA) (133.89 KB - PDF)

**First published:**

16/03/2022

[View](/da/documents/overview/sapropterin-dipharma-epar-medicine-overview_da.pdf)

Deutsch (DE) (138.2 KB - PDF)

**First published:**

16/03/2022

[View](/de/documents/overview/sapropterin-dipharma-epar-medicine-overview_de.pdf)

eesti keel (ET) (122.46 KB - PDF)

**First published:**

16/03/2022

[View](/et/documents/overview/sapropterin-dipharma-epar-medicine-overview_et.pdf)

ελληνικά (EL) (159.14 KB - PDF)

**First published:**

16/03/2022

[View](/el/documents/overview/sapropterin-dipharma-epar-medicine-overview_el.pdf)

français (FR) (136.82 KB - PDF)

**First published:**

16/03/2022

[View](/fr/documents/overview/sapropterin-dipharma-epar-medicine-overview_fr.pdf)

hrvatski (HR) (153.68 KB - PDF)

**First published:**

16/03/2022

[View](/hr/documents/overview/sapropterin-dipharma-epar-medicine-overview_hr.pdf)

italiano (IT) (133.22 KB - PDF)

**First published:**

16/03/2022

[View](/it/documents/overview/sapropterin-dipharma-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (163.96 KB - PDF)

**First published:**

16/03/2022

[View](/lv/documents/overview/sapropterin-dipharma-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (154.61 KB - PDF)

**First published:**

16/03/2022

[View](/lt/documents/overview/sapropterin-dipharma-epar-medicine-overview_lt.pdf)

magyar (HU) (158.41 KB - PDF)

**First published:**

16/03/2022

[View](/hu/documents/overview/sapropterin-dipharma-epar-medicine-overview_hu.pdf)

Malti (MT) (157.83 KB - PDF)

**First published:**

16/03/2022

[View](/mt/documents/overview/sapropterin-dipharma-epar-medicine-overview_mt.pdf)

Nederlands (NL) (134.72 KB - PDF)

**First published:**

16/03/2022

[View](/nl/documents/overview/sapropterin-dipharma-epar-medicine-overview_nl.pdf)

polski (PL) (158.04 KB - PDF)

**First published:**

16/03/2022

[View](/pl/documents/overview/sapropterin-dipharma-epar-medicine-overview_pl.pdf)

português (PT) (135.91 KB - PDF)

**First published:**

16/03/2022

[View](/pt/documents/overview/sapropterin-dipharma-epar-medicine-overview_pt.pdf)

română (RO) (153.14 KB - PDF)

**First published:**

16/03/2022

[View](/ro/documents/overview/sapropterin-dipharma-epar-medicine-overview_ro.pdf)

slovenčina (SK) (154.28 KB - PDF)

**First published:**

16/03/2022

[View](/sk/documents/overview/sapropterin-dipharma-epar-medicine-overview_sk.pdf)

slovenščina (SL) (151.97 KB - PDF)

**First published:**

16/03/2022

[View](/sl/documents/overview/sapropterin-dipharma-epar-medicine-overview_sl.pdf)

Suomi (FI) (132.01 KB - PDF)

**First published:**

16/03/2022

[View](/fi/documents/overview/sapropterin-dipharma-epar-medicine-overview_fi.pdf)

svenska (SV) (132.77 KB - PDF)

**First published:**

16/03/2022

[View](/sv/documents/overview/sapropterin-dipharma-epar-medicine-overview_sv.pdf)

Sapropterin Dipharma : EPAR - Risk management plan

English (EN) (117.56 KB - PDF)

**First published:** 16/03/2022

**Last updated:** 17/10/2025

[View](/en/documents/rmp/sapropterin-dipharma-epar-risk-management-plan_en.pdf)

## Product information

Sapropterin Dipharma : EPAR - Product Information

English (EN) (506.79 KB - PDF)

**First published:** 16/03/2022

**Last updated:** 03/02/2026

[View](/en/documents/product-information/sapropterin-dipharma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-570)

български (BG) (638 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/bg/documents/product-information/sapropterin-dipharma-epar-product-information_bg.pdf)

español (ES) (541.16 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/es/documents/product-information/sapropterin-dipharma-epar-product-information_es.pdf)

čeština (CS) (538.3 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/cs/documents/product-information/sapropterin-dipharma-epar-product-information_cs.pdf)

dansk (DA) (479.92 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/da/documents/product-information/sapropterin-dipharma-epar-product-information_da.pdf)

Deutsch (DE) (597.32 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/de/documents/product-information/sapropterin-dipharma-epar-product-information_de.pdf)

eesti keel (ET) (559.81 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/et/documents/product-information/sapropterin-dipharma-epar-product-information_et.pdf)

ελληνικά (EL) (612.89 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/el/documents/product-information/sapropterin-dipharma-epar-product-information_el.pdf)

français (FR) (573.2 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/fr/documents/product-information/sapropterin-dipharma-epar-product-information_fr.pdf)

hrvatski (HR) (567.22 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/hr/documents/product-information/sapropterin-dipharma-epar-product-information_hr.pdf)

íslenska (IS) (524.11 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/is/documents/product-information/sapropterin-dipharma-epar-product-information_is.pdf)

italiano (IT) (649.09 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/it/documents/product-information/sapropterin-dipharma-epar-product-information_it.pdf)

latviešu valoda (LV) (586.52 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/lv/documents/product-information/sapropterin-dipharma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (570.59 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/lt/documents/product-information/sapropterin-dipharma-epar-product-information_lt.pdf)

magyar (HU) (626.03 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/hu/documents/product-information/sapropterin-dipharma-epar-product-information_hu.pdf)

Malti (MT) (642.17 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/mt/documents/product-information/sapropterin-dipharma-epar-product-information_mt.pdf)

Nederlands (NL) (551.84 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/nl/documents/product-information/sapropterin-dipharma-epar-product-information_nl.pdf)

norsk (NO) (472.98 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/no/documents/product-information/sapropterin-dipharma-epar-product-information_no.pdf)

polski (PL) (624.86 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/pl/documents/product-information/sapropterin-dipharma-epar-product-information_pl.pdf)

português (PT) (513.08 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/pt/documents/product-information/sapropterin-dipharma-epar-product-information_pt.pdf)

română (RO) (612.35 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/ro/documents/product-information/sapropterin-dipharma-epar-product-information_ro.pdf)

slovenčina (SK) (601.88 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/sk/documents/product-information/sapropterin-dipharma-epar-product-information_sk.pdf)

slovenščina (SL) (587.23 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/sl/documents/product-information/sapropterin-dipharma-epar-product-information_sl.pdf)

Suomi (FI) (500.82 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/fi/documents/product-information/sapropterin-dipharma-epar-product-information_fi.pdf)

svenska (SV) (501.34 KB - PDF)

**First published:**

16/03/2022

**Last updated:**

03/02/2026

[View](/sv/documents/product-information/sapropterin-dipharma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000319636 18/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sapropterin Dipharma : EPAR - All authorised presentations

English (EN) (41.21 KB - PDF)

**First published:** 16/03/2022

[View](/en/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_en.pdf)

[Other languages (25)](#file-language-dropdown-330)

български (BG) (57.17 KB - PDF)

**First published:**

16/03/2022

[View](/bg/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.71 KB - PDF)

**First published:**

16/03/2022

[View](/es/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (65.14 KB - PDF)

**First published:**

16/03/2022

[View](/cs/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.76 KB - PDF)

**First published:**

16/03/2022

[View](/da/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.29 KB - PDF)

**First published:**

16/03/2022

[View](/de/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (47.02 KB - PDF)

**First published:**

16/03/2022

[View](/et/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (63.49 KB - PDF)

**First published:**

16/03/2022

[View](/el/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_el.pdf)

français (FR) (48.25 KB - PDF)

**First published:**

16/03/2022

[View](/fr/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (125.34 KB - PDF)

**First published:**

16/03/2022

[View](/hr/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.32 KB - PDF)

**First published:**

16/03/2022

[View](/is/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_is.pdf)

Gaeilge (GA) (44.39 KB - PDF)

**First published:**

16/03/2022

[View](/ga/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_ga.pdf)

italiano (IT) (48.16 KB - PDF)

**First published:**

16/03/2022

[View](/it/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (64.97 KB - PDF)

**First published:**

16/03/2022

[View](/lv/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (66.38 KB - PDF)

**First published:**

16/03/2022

[View](/lt/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (63.83 KB - PDF)

**First published:**

16/03/2022

[View](/hu/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.37 KB - PDF)

**First published:**

16/03/2022

[View](/mt/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (47.24 KB - PDF)

**First published:**

16/03/2022

[View](/nl/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.29 KB - PDF)

**First published:**

16/03/2022

[View](/no/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_no.pdf)

polski (PL) (66.42 KB - PDF)

**First published:**

16/03/2022

[View](/pl/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.38 KB - PDF)

**First published:**

16/03/2022

[View](/pt/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_pt.pdf)

română (RO) (64.38 KB - PDF)

**First published:**

16/03/2022

[View](/ro/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (64.64 KB - PDF)

**First published:**

16/03/2022

[View](/sk/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.48 KB - PDF)

**First published:**

16/03/2022

[View](/sl/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (47.19 KB - PDF)

**First published:**

16/03/2022

[View](/fi/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (47.45 KB - PDF)

**First published:**

16/03/2022

[View](/sv/documents/all-authorised-presentations/sapropterin-dipharma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sapropterin Dipharma Active substance sapropterin dihydrochloride International non-proprietary name (INN) or common name sapropterin Therapeutic area (MeSH) Phenylketonurias Anatomical therapeutic chemical (ATC) code A16AX07

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Sapropterin Dipharma is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.

Sapropterin Dipharma is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment.

## Authorisation details

EMA product number EMEA/H/C/005646

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Dipharma Arzneimittel GmbH

Offheimer Weg 33

Opinion adopted 16/12/2021 Marketing authorisation issued 16/02/2022 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sapropterin Dipharma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (125.45 KB - PDF)

**First published:** 20/02/2025

**Last updated:** 03/02/2026

[View](/en/documents/procedural-steps-after/sapropterin-dipharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sapropterin Dipharma : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (141.98 KB - PDF)

**First published:** 24/06/2022

**Last updated:** 20/02/2025

[View](/en/documents/procedural-steps-after/sapropterin-dipharma-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Sapropterin Dipharma : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/2232/2022

English (EN) (848.48 KB - PDF)

**First published:** 16/03/2022

[View](/en/documents/assessment-report/sapropterin-dipharma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sapropterin Dipharma

Adopted

Reference Number: EMA/CHMP/732482/2021

English (EN) (156.09 KB - PDF)

**First published:** 17/12/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sapropterin-dipharma_en.pdf)

#### News on Sapropterin Dipharma

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021) 17/12/2021

**This page was last updated on** 03/02/2026

## Share this page

[Back to top](#main-content)